Literature DB >> 190413

Reduced incidence of Marek's disease gross lymphomas in T-cell-depleted chickens.

J M Sharma, K Nazerian, R L Witter.   

Abstract

Chickens of line 7, highly susceptible to Marek's disease (MD), were depleted of T-cells by neonatal thymectomy, total-body gamma-irradiation, and multiple injections with antithymocyte serum. In two replicate experiments, significantly fewer gross lymphomas were present in T-cell-depleted chickens than in intact or in T-cell-depleted, reconstituted hatchmates; these findings provided evidence that T-cells may be the principal target for MD virus (MDV) transformation, T-cell depletion was not complete, and the presence of microscopic lesions in T-cell-depleted chickens was attributed to residual T-cells. Ten lymphomas from intact chickens and 2 lymphomas from a T-cell-depleted chicken were examined for cellular composition. All lymphomas consisted predominantly of T-cells. The results of this and other published studies indicated that T-cells may have a dual role in MD; They may serve as a target for lymphoma formation by MDV and also may participate in immune surveillance against the disease in resistant chickens.

Entities:  

Mesh:

Year:  1977        PMID: 190413     DOI: 10.1093/jnci/58.3.689

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  2 in total

1.  Cell-mediated immunity to tumor antigen in Marek's disease: susceptibility of effector cells to antithymocyte serum and enhancement of cytotoxic activity by Vibrio cholerae neuraminidase.

Authors:  J M Sharma
Journal:  Infect Immun       Date:  1977-10       Impact factor: 3.441

2.  Morphological and Immunohistochemical Examination of Lymphoproliferative Lesions Caused by Marek's Disease Virus in Breeder Chickens.

Authors:  Alessandro Stamilla; Antonino Messina; Lucia Condorelli; Francesca Licitra; Francesco Antoci; Massimiliano Lanza; Guido Ruggero Loria; Giuseppe Cascone; Roberto Puleio
Journal:  Animals (Basel)       Date:  2020-07-27       Impact factor: 2.752

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.